Q1 Earnings Forecast for CNTB Issued By HC Wainwright

Connect Biopharma Holdings Limited (NASDAQ:CNTB) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for shares of Connect Biopharma in a research note issued to investors on Monday, March 31st. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.26) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Connect Biopharma’s Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.12) EPS, FY2026 earnings at ($1.32) EPS, FY2027 earnings at ($0.52) EPS, FY2028 earnings at ($0.52) EPS and FY2029 earnings at ($0.22) EPS.

Connect Biopharma Trading Up 10.2 %

CNTB opened at $0.63 on Thursday. The firm’s 50 day simple moving average is $0.87 and its two-hundred day simple moving average is $1.06. Connect Biopharma has a 1-year low of $0.55 and a 1-year high of $2.31.

Hedge Funds Weigh In On Connect Biopharma

Institutional investors have recently bought and sold shares of the stock. Catalina Capital Group LLC purchased a new stake in Connect Biopharma in the fourth quarter worth about $66,000. Callan Capital LLC lifted its position in shares of Connect Biopharma by 91.3% during the 4th quarter. Callan Capital LLC now owns 80,000 shares of the company’s stock valued at $110,000 after buying an additional 38,177 shares in the last quarter. Finally, Choreo LLC bought a new position in shares of Connect Biopharma during the 4th quarter valued at approximately $204,000. 58.72% of the stock is owned by institutional investors.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.